CN103070992B - Medicine for treating high myopia macular hemorrhages - Google Patents
Medicine for treating high myopia macular hemorrhages Download PDFInfo
- Publication number
- CN103070992B CN103070992B CN201310026245.7A CN201310026245A CN103070992B CN 103070992 B CN103070992 B CN 103070992B CN 201310026245 A CN201310026245 A CN 201310026245A CN 103070992 B CN103070992 B CN 103070992B
- Authority
- CN
- China
- Prior art keywords
- grams
- radix
- medicine
- high myopia
- hemorrhage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicine for treating high myopia macular hemorrhages. The purpose of the invention is to select a natural Chinese herbal medicine for treating the disease and enabling the natural Chinese herbal medicine to work according to knowledge and treatment principle of pathogenesis of the high myopia macular hemorrhages in Chinese traditional medicine science. The medicine is prepared by the following components: 12 g achyranthes bidentata, 6 g rhizoma coptidis, 16 g folium isatidis, 12 g agaric, 12 g radix paeoniae alba, 15 g rhizoma belamcandae, 12 g selfheal, 8 g saussurea involucrata, 15 g radix scutellariae, 10 g sophora flavescens, 10 g radix lithospermi, 15 g golden cypress, 10 g radix bupleuri, 10 g medicated leaven and 10 g radix aucklandiae; and these components are uniformly mixed and crushed into fine powder and the fine powder is separately filled into bags and taken after meal.
Description
Technical field the invention belongs to technical field of Chinese medicines, relates to one and treats macular hemorrhage in high myopia medicine, the Chinese patent medicine of preparing taking Chinese herbal medicine as raw material specifically.
Background technology high myopia is one of commonly encountered diseases having a strong impact on visual function, it is the important complication of high myopia that near degeneration high myopia macula area and macula lutea changes, especially punctum luteum hemorrhage is the main cause that causes permanent low vision or blinding, current this disease of western medical treatment is taking troxerutin, hyaluronate sodium as main, but poor effect.Chinese medicine is huge potentiality for tool aspect this disease for the treatment of, therefore invent one and treat macular hemorrhage in high myopia medicine and treat this disease.
Summary of the invention the object of this invention is to provide one and treats macular hemorrhage in high myopia medicine, to overcome the deficiencies in the prior art.
The object of the invention is pathogenetic understanding and Therapeutic Principle thereof to macular hemorrhage in high myopia according to motherland's medical tradition medical science, with reference to modern pharmacological research, therefrom filter out this sick natural Chinese medicinal herb for the treatment of, by theory of Chinese medical science prescription, it is played a role.
Medicine of the present invention is made up of following component:
10 grams of 10 grams of Radix Aucklandiae of 10 grams of Massa Medicata Fermentata of 15 grams of Radix Bupleuri of 10 grams of Cortex Phellodendris of 10 grams of Radix Arnebiae (Radix Lithospermi)s of 15 grams of Radix Sophorae Flavescentiss of 8 grams of Radix Scutellariaes of 12 grams of Herba Saussureae Involueratae of 15 grams of Spica Prunellaes of 12 grams of Rhizoma Belamcandae of 12 grams of Radix Paeoniae Albas of 16 grams of Polyporus of 6 grams of Folium Isatidiss of 12 grams of Rhizoma Coptidis of Radix Achyranthis Bidentatae
Above-mentioned each component mix homogeneously is ground into 150 order fine powders, is distributed into bag, 6 grams, every packed medicated powder.One after each meal, one bag of every day, uses mixing in water for oral taking at twice.
Medicine of the present invention is Chinese medicine preparation, theoretical according to traditional Chinese medical science formula, select medicine rationally, blood circulation promoting and blood stasis dispelling, hemostasis hemopoietic, treating both the principal and secondary aspects of a disease.Medicine of the present invention, through clinical observation patient for many years, evident in efficacy, the macular hemorrhage in high myopia that a variety of causes is caused has remarkable result.
Clinical drug of the present invention is taken result and is shown, has following advantage:
It is raw material that the present invention selects natural plant, and each component meets pharmaceutical control law regulation, utilizes the comprehensive function treatment macular hemorrhage in high myopia of each taste medicine, without chemicals, nontoxic to human body, has no side effect, safe and reliable.The present invention is powder, and effective ingredient scatters and disappears few, and curative effect is high, cheap, and taking convenience, without any discomfort disease.Medicine of the present invention is obvious to macular hemorrhage in high myopia curative effect.Clinical drug of the present invention is observed, and can replace the medicine of other treatment macular hemorrhage in high myopia.
For showing the therapeutic effect of medicine of the present invention to macular hemorrhage in high myopia, the present invention is through the clinical observation of 88 routine macular hemorrhage in high myopia systems, and select medical history, the state of an illness, age and the macular hemorrhage in high myopia patient 86 examples as a comparison group suitable with traditional therapy, age 16-62 year, course of disease 1-6; Test group: the conventional medicine of stopping using, uses medicine of the present invention; Matched group: use conventional medicine.Observation period is 3 months, check after 3 months, and it is clear for curing that punctum luteum hemorrhage disappears, looks thing completely.Punctum luteum hemorrhage is most of to be absorbed, corrects defects of vision and improve more than 2 row as effective; Punctum luteum hemorrhage partially absorbs, corrects defects of vision and improves 1-2 behavior and take a turn for the better; After treatment, punctum luteum hemorrhage is invalid without absorbing, correct defects of vision without rising to.
Instructions of taking: 6 grams, every packed medicated powder.One after each meal, one bag of every day, uses mixing in water for oral taking at twice.Clinical comparison the results are shown in Table 1.
Table 1: use medicine of the present invention and the observation of curative effect that uses conventional medicine to macular hemorrhage in high myopia patient.
Two groups of curative effect comparisons of table 1 (example, %)
| Group | n | Recovery from illness | Effective | Take a turn for the better | Invalid | Total significant figure |
| Experimental group | 88 | 58(65.9) | 20(22.7) | 8(9.1) | 2(2.3) | 86(97.7) |
| Matched group | 86 | 38(44.2) | 18(20.9) | 14(16.3) | 16(18.6) | 70(81.4) |
Note: curative effect relatively adopts statistical method, enumeration data adopts X
2inspection, two groups of relatively P < 0.01 of effective percentage
As can be seen from Table 1, medicine of the present invention is to 88 routine macular hemorrhage in high myopia patients, recovery from illness have 58 examples, account for 69.5%, have 20 examples of remarkable result, account for 22.7%, improvement have 8 examples, account for 9.1%; Total effective rate reaches 97.7%.Use Drug therapy macular hemorrhage in high myopia of the present invention than using conventional medicament to have the superiority of significance.
Detailed description of the invention
Choose raw material by following proportioning:
10 grams of 10 grams of Radix Aucklandiae of 10 grams of Massa Medicata Fermentata of 15 grams of Radix Bupleuri of 10 grams of Cortex Phellodendris of 10 grams of Radix Arnebiae (Radix Lithospermi)s of 15 grams of Radix Sophorae Flavescentiss of 8 grams of Radix Scutellariaes of 12 grams of Herba Saussureae Involueratae of 15 grams of Spica Prunellaes of 12 grams of Rhizoma Belamcandae of 12 grams of Radix Paeoniae Albas of 16 grams of Polyporus of 6 grams of Folium Isatidiss of 12 grams of Rhizoma Coptidis of Radix Achyranthis Bidentatae; Above-mentioned each component mix homogeneously is ground into 150 order fine powders, is distributed into bag, 6 grams, every packed medicated powder.
Claims (1)
1. a treatment macular hemorrhage in high myopia medicine, is characterized in that it is the powder of being made up of the raw material of following weight proportioning: 12 grams of Radix Achyranthis Bidentataes, 6 grams of Rhizoma Coptidis, 16 grams of Folium Isatidiss, 12 grams of Polyporus, 12 grams of the Radix Paeoniae Albas, 15 grams of Rhizoma Belamcandae, 12 grams of Spica Prunellaes, 8 grams of Herba Saussureae Involueratae, 15 grams of Radix Scutellariaes, 10 grams of Radix Sophorae Flavescentiss, 10 grams of Radix Arnebiae (Radix Lithospermi)s, 15 grams of Cortex Phellodendris, 10 grams of Radix Bupleuri, 10 grams of Massa Medicata Fermentata, 10 grams of the Radix Aucklandiae; Above-mentioned each component mix homogeneously is ground into 150 order fine powders and get final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310026245.7A CN103070992B (en) | 2013-01-11 | 2013-01-11 | Medicine for treating high myopia macular hemorrhages |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310026245.7A CN103070992B (en) | 2013-01-11 | 2013-01-11 | Medicine for treating high myopia macular hemorrhages |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103070992A CN103070992A (en) | 2013-05-01 |
| CN103070992B true CN103070992B (en) | 2014-07-02 |
Family
ID=48147838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310026245.7A Expired - Fee Related CN103070992B (en) | 2013-01-11 | 2013-01-11 | Medicine for treating high myopia macular hemorrhages |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103070992B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104587094A (en) * | 2015-02-11 | 2015-05-06 | 陈红 | Pharmaceutical composition for treating macular hemorrhage in high myopia and application of pharmaceutical composition |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1362113A (en) * | 2001-01-04 | 2002-08-07 | 杨孟君 | Nano coptidis-goat liver meidcine and its preparation |
| CN1947753A (en) * | 2005-10-12 | 2007-04-18 | 尧光远 | Therapy method specially for treating eye diseases |
| CN101837066A (en) * | 2009-03-18 | 2010-09-22 | 复旦大学 | Application of golden thread detoxication decoction as compound preparation in preparing IOD active medicaments |
| CN102631558A (en) * | 2012-04-25 | 2012-08-15 | 李敏 | Medicament for treating eye disease and preparation method of medicament |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4933007B2 (en) * | 2001-09-21 | 2012-05-16 | ライオン株式会社 | Ophthalmic composition and method for enhancing antibacterial activity of the composition |
| KR100850263B1 (en) * | 2007-12-20 | 2008-08-04 | 박인수 | Feed additives for replacing antibiotics and method of manufacturing thereof |
| WO2010040232A1 (en) * | 2008-10-09 | 2010-04-15 | Waratah Pharmaceuticals Inc. | Use of scyllo-inositols for the treatment of macular degeneration-related disorders |
-
2013
- 2013-01-11 CN CN201310026245.7A patent/CN103070992B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1362113A (en) * | 2001-01-04 | 2002-08-07 | 杨孟君 | Nano coptidis-goat liver meidcine and its preparation |
| CN1947753A (en) * | 2005-10-12 | 2007-04-18 | 尧光远 | Therapy method specially for treating eye diseases |
| CN101837066A (en) * | 2009-03-18 | 2010-09-22 | 复旦大学 | Application of golden thread detoxication decoction as compound preparation in preparing IOD active medicaments |
| CN102631558A (en) * | 2012-04-25 | 2012-08-15 | 李敏 | Medicament for treating eye disease and preparation method of medicament |
Non-Patent Citations (7)
| Title |
|---|
| JP特开2003-95952A 2003.04.03 |
| 宋柯等.清解活血汤对兔自身免疫性视网膜血管炎病理学变化的影响.《中国中医眼科杂志》.2012,第22卷(第6期),第401-404页，尤其第401页左栏第1段，第402页左栏第1.1.2节，第404页左栏第2段至右栏第2段. |
| 李华.眼科血证的论治体会.《浙江中医药大学学报》.2008,第32卷(第1期),第46-47页，尤其第41页右栏第2节第1段，第42页左栏第2.3节. |
| 清解活血汤对兔自身免疫性视网膜血管炎病理学变化的影响;宋柯等;《中国中医眼科杂志》;20121231;第22卷(第6期);第401-404页，尤其第401页左栏第1段，第402页左栏第1.1.2节，第404页左栏第2段至右栏第2段 * |
| 眼科常用中药杂记;谷万章;《航空航天医药》;20041231;第15卷(第3期);第185-187页，尤其第185页第6节、第19节、第7节 * |
| 眼科血证的论治体会;李华;《浙江中医药大学学报》;20080131;第32卷(第1期);第46-47页，尤其第41页右栏第2节第1段，第42页左栏第2.3节 * |
| 谷万章.眼科常用中药杂记.《航空航天医药》.2004,第15卷(第3期),第185-187页，尤其第185页第6节、第19节、第7节. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103070992A (en) | 2013-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105362491A (en) | External-use medicine for treating cervical vertebra hyperosteogeny | |
| CN103505643B (en) | Medicament for treating postpartum urinary retention | |
| CN102743645B (en) | Chinese medicinal preparation for treating premature ejaculation | |
| CN101954042A (en) | Tumor eliminating capsule | |
| CN103070992B (en) | Medicine for treating high myopia macular hemorrhages | |
| CN104491684A (en) | Traditional Chinese medicine for treating insomnia and application thereof | |
| CN103705846A (en) | Traditional Chinese medicine preparation for treating ovarian cyst | |
| CN102727693A (en) | Compound propolis composition used for treating swine toxoplasmosis, and preparation method thereof | |
| CN103007237B (en) | Medicine for treating idiopathic thrombocytopenic purpura (ITP) | |
| CN104800799A (en) | Traditional Chinese medicament for treating endometrial thickening with ovarian cysts | |
| CN103071046B (en) | Medicine paste for treating high myopia macular hemorrhage | |
| CN101264197B (en) | Medicine for treating sciatica | |
| CN102526622B (en) | Medicine for treating knee-joint bursitis | |
| CN103599220A (en) | Compound propolis composition for treating pet acariasis disease, and preparation method thereof | |
| CN102552503B (en) | Traditional Chinese medicine powder used for treating cervical erosion | |
| CN102178777B (en) | Chinese patent drug for treating nervous breakdown | |
| CN106236899A (en) | A kind of Chinese medicine composition of anemofrigid-damp arthralgia | |
| CN103655875B (en) | Treatment blood sampling causes the medicine of Patients with Aplastic Anemia venous thrombosis | |
| CN105362758A (en) | Influenza treatment pharmaceutical composition containing radix platycodonis | |
| CN102973803A (en) | Drug for treating hematopathy primary thrombocytopenic purpura | |
| CN103550453B (en) | Promote Chinese medicine composition of poultry growing and fattening and preparation method thereof | |
| CN103285320A (en) | Traditional Chinese medicine composition for treating hyperosteogeny and preparation method thereof | |
| CN102961516B (en) | Pure Chinese medicine composition for the treatment of duck viral hepatitis and preparation method thereof | |
| CN102657813A (en) | Medicament for treating chronic leg ulcers | |
| CN104013754A (en) | Traditional Chinese medicine composition for treating old traumas of soft tissues of joints of limbs and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140702 Termination date: 20150111 |
|
| EXPY | Termination of patent right or utility model |